Related Experiment Videos
[Chemotherapy of osteosarcoma (author's transl)]
Deutsche Medizinische Wochenschrift (1946)
|December 16, 1977
Summary
The cyclic chemotherapy regimen OS I/75 shows promising results for osteosarcoma, with 6 primary patients achieving long-term remission. This treatment protocol offers effective management for osteosarcoma, including metastatic cases.
Area of Science:
- Oncology
- Pharmacology
Context:
- Osteosarcoma is a rare but aggressive bone cancer.
- Effective chemotherapy regimens are crucial for improving patient outcomes.
Purpose:
- To evaluate the efficacy and safety of the cyclic chemotherapy scheme OS I/75 in patients with newly diagnosed osteosarcoma and secondary metastases.
Summary:
- The OS I/75 regimen, comprising high-dose methotrexate with citrovorum-factor rescue, doxorubicin, and cyclophosphamide, was administered to 9 patients (6 primary, 3 metastatic).
- All 6 primary osteosarcoma patients achieved continuous remission (median 12+ months).
- Patients with metastases experienced remissions of 5.5+ and 8+ months. Hematological side effects caused manageable delays in treatment cycles. Two cases of doxorubicin-induced cardiomyopathy were noted.
Impact:
- The study highlights the potential of the OS I/75 regimen in achieving durable remission for osteosarcoma.
- It underscores the need for centralized patient care and interdisciplinary cooperation for optimal treatment strategies.
- A prospective treatment program has been developed for Germany and Austria.